AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is conducting a Phase III, double-blind, placebo-controlled, randomized study to evaluate the effects of combining durvalumab with oleclumab or monalizumab in patients with Stage III unresectable non-small cell lung cancer (NSCLC) who have not progressed following platinum-based chemoradiation therapy. This study aims to assess the efficacy and safety of these combinations, which could potentially enhance treatment outcomes for patients with this challenging condition.
The study involves three intervention groups: one receiving durvalumab with oleclumab, another with durvalumab and monalizumab, and a comparator group receiving durvalumab with a placebo. These drugs are administered via intravenous infusion, with the goal of improving patient response to treatment.
The study follows a randomized, parallel assignment model with quadruple masking to ensure unbiased results. The primary purpose is treatment-focused, aiming to provide new insights into effective NSCLC therapies.
The study began on February 7, 2022, with a primary completion date yet to be announced. The latest update was submitted on July 22, 2025, indicating ongoing progress and data collection.
This clinical update could positively influence AstraZeneca’s stock performance by reinforcing its commitment to advancing cancer treatments. The study’s results may also impact investor sentiment, particularly if the outcomes demonstrate significant improvements over existing therapies, potentially setting a new standard in NSCLC treatment.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.